Who
Timothy Coughlin
Director
Company insider
Files Form 4 as: Director, Travere Therapeutics; Director, Vir Biotechnology; Director, ADC Therapeutics SA; Director, aTyr Pharma; Director, Fate Therapeutics; Chief Financial Officer, Neurocrine Biosciences.
In numbers
- Trades disclosed
- 180
- Buys
- 2
- Sells
- 36
- Bought
- $237K
- Sold
- $14.4M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 11 Jan 2007
- Last trade
- 12 Jun 2026
- Last filed
- 16 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 16 Jun 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $265K10,000 at $26.52 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $501K10,000 at $50.07 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $265K10,000 at $26.52 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $501K10,000 at $50.07 | filing |
| 9 Jun 2026filed 10 Jun 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $39K12,600 at $3.08 | filing |
| 3 Jun 2026filed 3 Jun 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $39K12,600 at $3.08 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
News
Travere (NASDAQ: TVTX) CEO sells 243,735 shares after option exercisesTVTX · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Timothy Coughlin; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.